BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis

Reuters11-07

Nov 7 (Reuters) - Palisade Bio Inc PALI.O:

PALISADE BIO ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL STUDY OF PALI-2108 FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC)

Source text: ID:nGNX55TlWz

Further company coverage: PALI.O

(Reuters.Briefs@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481188830?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481188830","market":"us","top_or_hot":-1,"title":"BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis</title></head><body><p><span>Nov 7 (Reuters)</span><span> - </span>Palisade Bio Inc <span>PALI.O</span>:</p><ul><li><p>PALISADE BIO ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL STUDY OF PALI-2108 FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC)</p></li></ul><p>Source text: <span>ID:nGNX55TlWz</span></p><p>Further company coverage: <span>PALI.O</span></p><p> (Reuters.Briefs@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 21:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABPWJC6:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative ColitisNov 7 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABPWJC6:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PALI","symbol_name":"Palisade Bio Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUABPWJC6:1","article_id":"2481188830","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481188830","pubTimestamp":1730987955,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative ColitisNov 7 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PALI":"Palisade Bio Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"BRIEF-Palisade Bio宣布Pali-2108治疗中重度溃疡性结肠炎的1期临床研究中首例受试者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PALI":0.9},"content_text":"BRIEF-Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative ColitisNov 7 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL STUDY OF PALI-2108 FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS (UC)Source text: ID:nGNX55TlWzFurther company coverage: PALI.O (Reuters.Briefs@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481188830"}